Clinical Trial Update: DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the effect of dapagliflozin on exercise capacity in heart failure with reduced ejection fraction using a 6-minute walk test; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF) | Phase 3 | Status: COMPLETED | Results posted: 2021-05-05